Rarefind you're absolutely right with regard to the accelerated approval potential of IMUC's ICT based on its superior trial design and orphan drug status. We've covered this topic many times before and are confident that such a notion is not properly reflected in the price.
With regard to NWBO secondary, offering on spikes reeks of dilution machine tactics, they should have let the stock run as it had much more room.
Their management is just highly questionable. Also, I've heard from two separate sources now that LInda Powers was some kind of VP at Enron...which would explain her past record of screwing NWBO shareholders.
News 
Market Data 
Discover 
AI
